Gadolinium-based particles show and treat tumours

October 27, 2015, Kawasaki Innovation Gateway Skyfront
Gadolinium-based particles show and treat tumours
Scheme of Gd-DTPA/CaP hybrid micelles targeting tumours for gadolinium neutron capture therapy (GdNCT). (a) The accumulation of Gd-DTPA delivered by Gd-DTPA/CaP in tumours due to the enhanced permeation and retention effect. (b) Low energy thermal neutron irradiation does not kill normal cells without NCT agents. (c) Thermal neutron irradiation could kill or cause hazardous damage to cancer cells by the gamma rays emitted from the Gd nuclides after nuclear reaction with captured thermal neutrons. Credit: 2015 The American Chemical Society

Neutron-capture therapy (NCT) provides an effective localised treatment for irradiating cancer tumours. However to ensure only cancerous cells are destroyed it is helpful to see where NCT drugs have accumulated in order to target their activation only in tumours.

Now a collaboration led by researchers at the Kawasaki Institute of Industry Promotion in Japan has demonstrated cancer imaging and treatment using gadolinium-based nanoparticles in living mice.

Absorption of harmless low-energy thermal neutrons can trigger fission in stable elements including lithium, boron, gadolinium and uranium, releasing high-energy particles and gamma radiation that destroy nearby . Therefore, NCT has the potential advantage of attacking cells across a whole tumour. Among those elements, gadolinium is useful, because is used for MRI imaging.

Dr. Kazunori Kataoka and colleagues at Kawasaki Institute of Industry Promotion, Tokyo Institute of Technology, The University of Tokyo, National Institute of Radiological Sciences and Kyoto University in Japan delivered a gadolinium-based clinical MRI contrast agent - Gd-DTPA - to . They encased the drug in CaP micelles that ensured preferential uptake by and stayed intact while in the blood only disintegrating to release the gadolinium compounds once in tumour cells in response to the change in pH.

"The Gd-DTPA/CaP showed a dramatically increased accumulation of Gd-DTPA in tumours, leading to the selective contrast enhancement of tumour tissues for precise tumor location by MRI," state the researchers in their report. "The enhanced tumour-to-blood distribution ratio of Gd-DTPA/CaP resulted in the effective suppression of without loss of body weight, indicating the potential of Gd-DTPA/CaP for safe cancer treatment."

Explore further: New imaging process provides better picture of tumours

More information: Peng Mi et al. Hybrid Calcium Phosphate-Polymeric Micelles Incorporating Gadolinium Chelates for Imaging-Guided Gadolinium Neutron Capture Tumor Therapy, ACS Nano (2015). DOI: 10.1021/acsnano.5b00532

Related Stories

New imaging process provides better picture of tumours

October 12, 2012

Cancer remains one of the leading causes of death in Europe and the world, and early detection and treatment remains vital in the fight. Researchers in Norway have validated a method of non-invasive imaging that they believe ...

Simplified boron compound may treat brain tumours

September 16, 2015

Effective and targeted uptake among malignant cells demonstrates the promise of a simplified boron compound for neutron radiation therapy, report researchers at Okayama University and Kinki University.

Molecular MRI aims at component of multiple cancers

June 8, 2015

A relatively new biomarker called prostate-specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor ...

Contrast agent linked with brain abnormalities on MRI

December 17, 2013

For the first time, researchers have confirmed an association between a common magnetic resonance imaging (MRI) contrast agent and abnormalities on brain MRI, according to a new study published online in the journal Radiology. ...

Recommended for you

Engineers produce smallest 3-D transistor yet

December 10, 2018

Researchers from MIT and the University of Colorado have fabricated a 3-D transistor that's less than half the size of today's smallest commercial models. To do so, they developed a novel microfabrication technique that modifies ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.